Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    Tk2d

A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04581733
Recruitment Status : Not yet recruiting
First Posted : October 9, 2020
Last Update Posted : December 19, 2020
Sponsor:
Collaborator:
Zogenix, Inc.
Information provided by (Responsible Party):
Modis Therapeutics, Inc.

Brief Summary:
This is a Phase 3, prospective, multicenter, open-label treatment study of the efficacy and safety of MT1621 in patients with thymidine kinase 2 deficiency (TK2d). In order to be eligible for this study, participants must have genetic confirmation of TK2d and must not have ever received MT1621 or nucleos(t)ides before entering the study.

Condition or disease Intervention/treatment Phase
Thymidine Kinase 2 Deficiency Drug: MT1621 Phase 3

Detailed Description:

Thymidine kinase 2 (TK2) is a protein involved in the normal function of mitochondria. Thymidine kinase 2 deficiency (TK2d) is a form of mitochondrial DNA depletion syndrome and is a very rare inherited genetic disorder. TK2d leads to abnormally low amounts of DNA in mitochondria and because of the low amount of DNA, the mitochondria are not able to provide the energy that cells need to function properly, which causes severe muscle weakness that can progress until patients lose the ability to stand, walk, eat, and breathe independently. There are no FDA-approved medicines to treat TK2d.

MT1621 is a therapy that targets the underlying pathophysiology of TK2d by restoring mitochondrial DNA (mtDNA) replication fidelity. MT1621 consists of a combination of deoxynucleosides (the building blocks of mtDNA) given orally. Deoxynucleoside combination therapy improves nucleotide balance, increases mtDNA copy number, improves cell function, and prolongs life in preclinical models of TK2d.

This is a Phase 3, prospective, multicenter, open-label treatment study to assess the efficacy and safety of MT1621 in patients with TK2d. In order to be eligible for this study, participants must have the TK2d genetic mutation and must not have ever received MT1621 or nucleos(t)ides before entering the study.

Participants who meet entry criteria will be enrolled in one of the following two groups depending on their age at time of enrollment:

Group A: ≤12 years of age. Participants will receive MT1621 on Day 1 for up to 24 months and complete study visits every 3 months where they will undergo safety, motor milestone, and functional efficacy assessments.

Group B: >12 years of age. Participants will undergo up to a 9-month run-in phase where they will complete safety and efficacy assessments only to better characterize the natural course of late-onset TK2d. Once the run-in phase is complete or upon meeting the escape rules during the run-in phase (defined as an objective decline in motor or respiratory status per protocol), participants will receive MT1621 and complete safety, motor milestone, and functional efficacy assessments for up to 39 months.

Once all participants have completed the treatment phase as described above, they will complete a final follow-up contact 4 weeks after the last dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

All participants will receive MT1621 up to a maximum of 400 mg/kg/day

Eligible participants will enter 1 of 2 groups:

  • Group A: approximately 10 participants aged ≤12.0 years will receive MT1621 on Day 1
  • Group B: approximately 15 participants aged >12.0 years will receive MT1621 after completing an up to 9-month run-phase
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Single Arm Clinical Study to Evaluate the Efficacy and Safety of MT1621 in Subjects With Thymidine Kinase 2 (TK2) Deficiency
Estimated Study Start Date : December 2020
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : April 2025

Arm Intervention/treatment
Experimental: Participants ≤12.0 years (Group A)
Group A: Male or female participants ≤12.0 year old. All participants will receive MT1621 starting on Day 1
Drug: MT1621
All patients will receive MT1621 up to a maximum of 400 mg/kg/day each dC and dT, as tolerated
Other Name: Deoxycytidine (dC) and deoxythymidine (dT)

Experimental: Participants >12.0 years (Group B)
Group B: Male or female participants >12.0 years old (≤7 participants on ventilatory support) All participants will complete a 9-month run-in phase (MT1621 will not be administered). After the completion of the 9-month run-in phase, all participants will receive MT1621.
Drug: MT1621
All patients will receive MT1621 up to a maximum of 400 mg/kg/day each dC and dT, as tolerated
Other Name: Deoxycytidine (dC) and deoxythymidine (dT)




Primary Outcome Measures :
  1. Time to Loss of Any Motor Milestone [ Time Frame: 24 months ]
    Risk of loss of any motor milestone (e.g., head control, rolling, standing, walking, jumping, hopping, running): Occurrence of loss of any motor milestone will be considered an event and the duration for event will be calculated as time from first MT1621 treatment date to the first date any of the motor milestones are lost. Patients who do not lose any milestone will be censored and their duration period will be the time from first MT1621 treatment date and the last contact date.


Secondary Outcome Measures :
  1. Time to Acquisition of Any Motor Milestone [ Time Frame: 24 months ]
    Probability of acquisition of any motor milestone (e.g., head control, rolling, sitting, standing, walking, jumping, hopping, running): Occurrence of acquiring any motor milestone will be considered an event and the duration for event will be calculated as time from first MT1621 treatment date to the first date of acquiring any motor milestones. Patients who do not acquire any milestone will be censored and their duration period will be the time from first MT1621 treatment date and the last contact date.

  2. Overall Survival [ Time Frame: 24 months ]
    Risk of death: Occurrence of death will be considered an event and the duration for event will be calculated as time from first MT1621 treatment date to death date. Patients who survived will be censored and their duration period will be the time from first MT1621 treatment date and the last contact date.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of TK2 deficiency based on confirmed disease-causing mutation(s) in the TK2 gene
  • Absence of other confirmed genetic disease or polygenic disease that may confound evaluation of the efficacy of treatment for TK2 deficiency

Additional Inclusion Criteria, Evidence of a motor deficit:

  • Group A: Significant loss or decline (regression) in previously achieved motor milestones or developmental delay in achieving motor milestones
  • Group B: Unable to perform at least one of the motor milestones

Exclusion Criteria:

  • History of liver disease, or liver function test results (alanine aminotransferase [ALT], aspartate transaminase [AST], or total bilirubin) ≥2× upper limit of normal at Screening without prior Sponsor approval
  • EtCO2>45 mmHg if not on ventilatory support

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04581733


Contacts
Layout table for location contacts
Contact: Zogenix Clinical Trials Information Desk 510-338-9968 MT1621ClinStudyInfo@zogenix.com

Sponsors and Collaborators
Modis Therapeutics, Inc.
Zogenix, Inc.
Investigators
Layout table for investigator information
Study Director: Joanne Quan, MD Modis Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Modis Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04581733    
Other Study ID Numbers: MT-1621-104
First Posted: October 9, 2020    Key Record Dates
Last Update Posted: December 19, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Modis Therapeutics, Inc.:
TK2d
TK2
mitochondrial disorder
mitochondrial disease
Mitochondria
deoxythymidine/deoxythymidine substrate enhancement therapy
dC/dT
deoxythymidine/deoxythymidine
primary mitochondrial myopathy
mitochondrial depletion syndrome
Muscle weakness
Muscle atrophy
Loss of mobility